A 20-Amino-Acid Peptide Dramatically Improves Cardiac Arrest Survival in Mice and Pigs by Mimicking Cooling Protection | Research

The takeaway

A cell-penetrating peptide called TAT-PHLPP9c, given intravenously during CPR, significantly improved survival, heart function, and brain function after cardiac arrest in both mouse and pig models — mimicking the protective effects of therapeutic cooling without the need for physical cooling.

>90% cardiac arrest mortality
Current out-of-hospital cardiac arrest mortality rate — TAT-PHLPP9c is the first peptide drug to significantly improve long-term survival in preclinical models

What the researchers found

TAT-PHLPP9c, a 20-amino acid cell-penetrating peptide, administered intravenously during CPR after 12-minute asystolic arrest in mice significantly improved return of spontaneous circulation, mean arterial blood pressure, cerebral blood flow, cardiac and neurological function, and survival at both 4 hours and 5 days.

Mechanistically, the peptide works by inhibiting PHLPP1, enhancing AKT activation (but not PKC), decreasing pyruvate dehydrogenase phosphorylation and sorbitol production, and increasing ATP generation in heart and brain. It also reduced plasma taurine and glutamate — markers of cell damage. Critically, these protective benefits were validated in a swine model of ventricular fibrillation cardiac arrest, providing strong translational evidence.

Why it matters

Out-of-hospital cardiac arrest has a mortality rate exceeding 90%, and despite decades of research, no medication improves long-term survival. Therapeutic cooling helps but is extremely difficult to implement in emergency settings. A simple IV injection that mimics cooling's protective effects could be administered by paramedics during CPR — potentially saving hundreds of thousands of lives annually worldwide.

How the study worked

Complementary studies in mouse and swine cardiac arrest models. C57BL/6 mice were randomized (blinded) into saline control and peptide-treatment groups after 12-minute asystolic arrest, with TAT-PHLPP9c administered IV during CPR. Outcomes included return of circulation, blood pressure, cerebral blood flow, cardiac and neurological function, and survival (4-hour and 5-day). Biochemical analyses measured PHLPP signaling, AKT/PKC phosphorylation, metabolic markers, and plasma biomarkers. Validation was performed in a swine ventricular fibrillation arrest model.

What this study cannot tell us

This is preclinical research in animals, not humans. While the swine model provides strong translational evidence, human cardiac arrest involves additional complexities (comorbidities, variable arrest times, bystander CPR quality). The optimal dose, timing window, and safety profile in humans have not been established. The study used controlled laboratory conditions that differ from real-world emergency scenarios.

How to read the evidence

This is a rigorous preclinical study published in the Journal of Clinical Investigation with blinded randomized mouse experiments and validation in a large animal (swine) model — the gold standard for preclinical cardiac arrest research before human trials. The multi-species approach and mechanistic depth significantly strengthen the findings.

When this study was published

Published in 2023, this study represents cutting-edge research in resuscitation science. Clinical translation would require Phase I/II human trials, which could be underway or planned given the strength of the preclinical data and the unmet medical need.

The bigger picture

This represents a new paradigm in emergency medicine: pharmacological mimicry of therapeutic hypothermia. While cooling during CPR is one of the few interventions proven to improve cardiac arrest outcomes, logistical barriers limit its use. A peptide drug that activates the same protective pathways and can be drawn from a vial and injected during CPR could be as transformative for cardiac arrest as tPA was for stroke — bringing advanced neuroprotection out of the ICU and into the field.

Questions still open

What is the time window for TAT-PHLPP9c administration — can it still be effective if given later during prolonged CPR or after return of circulation?
Are there any safety concerns with AKT activation in the cardiac arrest setting, given AKT's role in cell growth and cancer?
Could TAT-PHLPP9c be combined with physical cooling for even greater neuroprotection in settings where both are available?

Common questions

How does this peptide mimic the effects of cooling after cardiac arrest?

Therapeutic cooling protects the heart and brain after cardiac arrest by activating protective cell pathways, including one controlled by a protein called AKT. The peptide TAT-PHLPP9c blocks an enzyme (PHLPP1) that normally keeps AKT switched off. By removing this brake, the peptide boosts AKT signaling, which increases energy production (ATP) in the heart and brain, reduces cell damage, and improves organ function — essentially achieving what cooling does, but through a simple injection.

Why is this study significant for emergency medicine?

No drug currently improves long-term survival after cardiac arrest — the only proven intervention (therapeutic cooling) is difficult to implement in the field. A peptide that can be kept in an ambulance and injected during CPR would be a game-changer, potentially saving tens of thousands of lives annually. The fact that it worked in both mice and pigs (whose hearts are similar to humans) makes it one of the most promising cardiac arrest treatments in the research pipeline.

Read the original research

A cell-penetrating PHLPP peptide improves cardiac arrest survival in murine and swine models.

The Journal of clinical investigation, 133(9)

View on PubMed ↗Publisher’s paper ↗

Citation

Li, Jing; Zhu, Xiangdong; Oberdier, Matt T; Lee, Chunpei; Lin, Shaoxia; Fink, Sarah J; Justice, Cody N; Qin, Kevin; Begeman, Andrew W; Damen, Frederick C; Kim, Hajwa; Chen, Jiwang; Cai, Kejia; Halperin, Henry R; Vanden Hoek, Terry L. (2023). A cell-penetrating PHLPP peptide improves cardiac arrest survival in murine and swine models.. The Journal of clinical investigation, 133(9). https://doi.org/10.1172/JCI164283